References
- Lee WM. Drug-induced acute liver failure. Clin Liver Dis 2013;17(4):575-86
- Chen M, Vijay V, Shi Q, et al. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today 2011;16(15-16):697-703
- Roth RA, Ganey PE. Intrinsic versus idiosyncratic drug-induced hepatotoxicity -- two villains or one? J Pharmacol Exp Ther 2010;332(3):692-7
- Chen M, Bisgin H, Tong L, et al. Toward predictive models for drug-induced liver injury in humans: are we there yet? Biomark Med 2014;8(2):201-13
- Lewis JH. Drug-induced liver injury, dosage, and drug disposition: is idiosyncrasy really unpredictable? Clin Gastroenterol Hepatol 2014. [Epub ahead of print]
- Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B* 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009;41(7):816-19
- Urban TJ, Shen Y, Stolz A, et al. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics 2012;22(11):784
- Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 2013;58(2):777-87
- Nonclinical assessment of potential hepatotoxicity in man. Available from: www.fda.gov/downloads/drugs/scienceresearch/researchareas/ucm091453.pdf [Last accessed March 2014]
- Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000;32(1):56-67
- Bjornsson ES, Bergmann OM, Bjornsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013;144(7):1419-25. e1413
- Garcia-Cortes M, Stephens C, Lucena MI, et al. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol 2011;55(3):683-91
- Teschke R, Frenzel C, Wolff A, et al. Drug induced liver injury: accuracy of diagnosis in published reports. Ann Hepatol 2014;13(2):248-55
- Anderson N, Borlak J. Correlation versus causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting. PLoS One 2011;6(10):e25221
- Steuerwald NM, Foureau DM, Norton HJ, et al. Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One 2013;8(12):e81974
- Shaw PJ, Hopfensperger MJ, Ganey PE, Roth RA. Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Toxicol Sci 2007;100(1):259-66
- Cosgrove BD, King BM, Hasan MA, et al. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 2009;237(3):317-30
- Senior JR. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future. Clin Pharmacol Ther 2012;92(3):332-9
- Guidance for industry drug-induced liver injury: premarketing clinical evaluation. Available from: www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf [Last accessed March 2014]
- Li AP. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the “multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 2002;142(1-2):7-23
- Chen M, Zhang J, Wang Y, et al. Liver toxicity knowledge base (LTKB) – a systems approach to a complex endpoint. Clin Pharmacol Ther 2013;95(5):409-12
- Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013;58(1):388-96